FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients

{
  "signal_id": "16381664-71b6-addf-2f80-e854db9f7471",
  "signal_type": "news",
  "signal_subtype": "launches",
  "detected_at": "2026-08-27T21:49:18+00:00",
  "company": {
    "name": "Gilead",
    "domain": "gilead.com"
  },
  "data": {
    "url": "https://www.cnbc.com/2026/08/27/fda-approves-gilead-hiv-pill-bixlenvo-designed-to-simplify-treatment.html",
    "title": "FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients",
    "excerpt": "In this article The Food and Drug Administration approved a once-daily HIV pill from Gilead that could help simplify care for some patients, the company announced Thursday. The drug, marketed as Bixlenvo, is aimed at patients whose virus is already under control but who remain on complicated treatment regimens. It could also appeal to those who simply want to switch to a new treatment alternative. The tablet combines bictegravir, the backbone of Gilead's blockbuster HIV pill Biktarvy, with lenacapavir, a first-in-class capsid inhibitor that has become a centerpiece of the company's long-term strategy for HIV treatment and prevention. The approval makes the new pill the first single-tablet regimen available for adults with HIV whose virus is suppressed but are unable to use currently available one-pill treatment options, according to Gilead. That population accounts for an estimated 5% or more of individuals in the U.S. living with HIV, the company told CNBC. The list price of the pill before discounts or rebates is $4,595 for a 30-day supply, which is in line with other daily single-tablet HIV treatments, Gilead told CNBC. People without health insurance may be eligible to get Bixlenvo for free through Gilead's patient assistance program, while those with commercial or private insurance may be able to receive co-pay support through another savings program, the company said...",
    "product": "Bixlenvo",
    "summary": "Gilead Sciences launched its new once-daily HIV pill, Bixlenvo, after receiving approval from the U.S. Food and Drug Administration.",
    "location": "United States",
    "planning": false,
    "image_url": "https://image.cnbcfm.com/api/v1/image/108355149-1787838771893-Untitled-1.jpg?v=1787838821&w=1920&h=1080",
    "confidence": 0.95,
    "product_data": {
      "name": "Bixlenvo",
      "full_text": "once-daily HIV pill from Gilead",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-08-27T21:49:18Z",
    "location_data": [
      {
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-08-27",
    "article_sentence": "The Food and Drug Administration approved a once-daily HIV pill from Gilead that could help simplify care for some patients, the company announced Thursday."
  }
}

curl https://signals.autobound.ai/v1/signals/16381664-71b6-addf-2f80-e854db9f7471 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"gilead.com","limit":20}'